Last reviewed · How we verify
Universidade Federal do Ceara — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| chlorhexidine digluconate | chlorhexidine digluconate | marketed | Antimicrobial agent / Antiseptic | Bacterial cell membrane and proteins | Infectious Disease / Oral Care | |
| NAC + Bromhexine (BMX) | NAC + Bromhexine (BMX) | phase 3 | Mucolytic/secretolytic combination | Respiratory/Pulmonology |
Therapeutic area mix
- Infectious Disease / Oral Care · 1
- Other · 1
- Respiratory/Pulmonology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- HaEmek Medical Center, Israel · 1 shared drug class
- Instituto de Investigacion Sanitaria La Fe · 1 shared drug class
- Johns Hopkins University · 1 shared drug class
- The Cooper Health System · 1 shared drug class
- Universidad de Guanajuato · 1 shared drug class
- University of Milan · 1 shared drug class
- University of Oslo · 1 shared drug class
- University of Pavia · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Universidade Federal do Ceara:
- Universidade Federal do Ceara pipeline updates — RSS
- Universidade Federal do Ceara pipeline updates — Atom
- Universidade Federal do Ceara pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Universidade Federal do Ceara — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidade-federal-do-ceara. Accessed 2026-05-17.